Mesoblast Limited (ASX: MSB)- Mesoblast’s stock climbed on FY18 revenue growth

Mesoblast LTD

Mesoblast Limited (ASX: MSB) today announced full year financial results for the 12 months ended 30 June 2018.  Revenue increased by US$14.8 million to US$17.3 million benefitting from commercialization revenue on sales of TEMCELL and payments received from Takeda in FY18.

Loss after tax has narrowed down from US$76.8 million in previous year to US$35.3 million in fiscal 2018.  There has been substantial reduction in operating net cash outflow by 21% to US$75 million on the back of increased revenue and less spend on manufacturing for R&D. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

In a strategic financing facility, Mesoblast is expected to receive additional US$50.0 million under existing agreements with Hercules Capital and NovaQuest. The company has neither paid nor anticipates paying any dividend.

Mesoblast’s stock edged up 4.823% to $1.630 on 30 August 2018 (7:24 PM AEST).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report